Cargando…

Phase III, randomized, double-blind, placebo-controlled, multicenter study of lipegfilgrastim in patients with non-small cell lung cancer receiving myelosuppressive therapy

PURPOSE: The aim of this study was to demonstrate lipegfilgrastim superiority versus placebo in adults with non-small cell lung cancer receiving myelosuppressive chemotherapy. METHODS: This phase III, double-blind study randomized chemotherapy-naive patients to receive cisplatin and etoposide with e...

Descripción completa

Detalles Bibliográficos
Autores principales:	Volovat, Constantin, Bondarenko, Igor M, Gladkov, Oleg A, Elsässer, Reiner, Buchner, Anton, Bias, Peter, Müller, Udo
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer International Publishing 2015
Materias:	Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4489970/ https://www.ncbi.nlm.nih.gov/pubmed/26155455 http://dx.doi.org/10.1186/s40064-015-1067-7

Ejemplares similares

A randomized, double-blind, active control, multicenter, dose-finding study of lipegfilgrastim (XM22) in breast cancer patients receiving myelosuppressive therapy
por: Buchner, Anton, et al.
Publicado: (2014)

Efficacy and safety of lipegfilgrastim versus pegfilgrastim: a randomized, multicenter, active-control phase 3 trial in patients with breast cancer receiving doxorubicin/docetaxel chemotherapy
por: Bondarenko, Igor, et al.
Publicado: (2013)

Immunogenicity Assessment of Lipegfilgrastim in Patients with Breast Cancer Receiving Chemotherapy
por: Zou, Linglong, et al.
Publicado: (2016)

A pharmacokinetic study of lipegfilgrastim in children with Ewing family of tumors or rhabdomyosarcoma
por: Belogurova, Margarita B., et al.
Publicado: (2016)

Review on lipegfilgrastim
por: Gasparic, Maja, et al.
Publicado: (2015)

Epoetin Theta in Anaemic Cancer Patients Receiving Platinum-Based Chemotherapy: A Randomised Controlled Trial
por: Tjulandin, Sergei A, et al.
Publicado: (2010)

Epoetin Theta with a New Dosing Schedule in Anaemic Cancer Patients Receiving Nonplatinum-Based Chemotherapy: A Randomised Controlled Trial
por: Tjulandin, Sergei A, et al.
Publicado: (2011)

Role of lipegfilgrastim in the management of chemotherapy-induced neutropenia
por: Hoggatt, Jonathan, et al.
Publicado: (2015)

Role of lipegfilgrastim in the management of chemotherapy-induced neutropenia [Corrigendum]
Publicado: (2015)

Lipegfilgrastim in the management of chemotherapy-induced neutropenia of cancer patients
por: Guariglia, Roberto, et al.
Publicado: (2016)

Efficacy and safety of lipegfilgrastim versus pegfilgrastim in elderly patients with aggressive B cell non-Hodgkin lymphoma (B-NHL): results of the randomized, open-label, non-inferiority AVOID neutropenia study
por: Link, Hartmut, et al.
Publicado: (2020)

Meta-analysis and indirect treatment comparison of lipegfilgrastim with pegfilgrastim and filgrastim for the reduction of chemotherapy-induced neutropenia-related events
por: Bond, T Christopher, et al.
Publicado: (2017)

An observational study of dose dense chemotherapy with lipegfilgrastim support in early breast cancer
por: Rashed, Ahmed, et al.
Publicado: (2023)

Pooled Analysis on the Effectiveness and Safety of Lipegfilgrastim in Patients With Urological Malignancies in the Real-World Setting
por: Merseburger, Axel S., et al.
Publicado: (2021)

Comparison of EP2006, a filgrastim biosimilar, to the reference: a phase III, randomized, double-blind clinical study in the prevention of severe neutropenia in patients with breast cancer receiving myelosuppressive chemotherapy
por: Blackwell, K., et al.
Publicado: (2015)

Patterns of granulocyte colony–stimulating factor prophylaxis in patients with cancer receiving myelosuppressive chemotherapy
por: Gawade, Prasad L., et al.
Publicado: (2020)

Prescribing patterns from medical chart abstraction of patients administered lipegfilgrastim: a pilot study in Europe
por: Kaplan, Sigal, et al.
Publicado: (2019)

Piperacillin/tazobactam Induced Myelosuppression
por: Lee, Kirsty Wai Chung, et al.
Publicado: (2009)

Letter to the editor: no increased febrile neutropenia risk to cancer patients receiving lipegfilgrastim—correction of a systematic review and meta-analysis of randomized controlled trials with G-CSF
por: Lehmacher, W., et al.
Publicado: (2016)

Double-Blind, Placebo-Controlled Study of Bezlotoxumab in Children Receiving Antibacterial Treatment for Clostridioides difficile Infection (MODIFY III)
por: Sferra, Thomas J, et al.
Publicado: (2023)

Translational Modeling of Drug‐Induced Myelosuppression and Effect of Pretreatment Myelosuppression for AZD5153, a Selective BRD4 Inhibitor
por: Collins, TA, et al.
Publicado: (2017)

Myelosuppression and kinase selectivity of multikinase angiogenesis inhibitors
por: Kumar, R, et al.
Publicado: (2009)

Myelosuppression by sunitinib is flt-3 genotype dependent
por: van Erp, N P, et al.
Publicado: (2010)

Sleeping through the storm: Preventing myelosuppression with quizartinib
por: Taylor, Samuel J., et al.
Publicado: (2017)

Antineoplastics: Myelosuppression and COVID-19: case report
Publicado: (2020)

Palbociclib: Myelosuppression and gastrointestinal reactions: case report
Publicado: (2022)

Cost-Utility Analysis of Lipegfilgrastim Compared to Pegfilgrastim for the Prophylaxis of Chemotherapy-Induced Neutropenia in Patients with Stage II-IV Breast Cancer
por: Akpo, Esse I. H., et al.
Publicado: (2017)

Higher incidence of pegfilgrastim-induced bone pain in younger patients receiving myelosuppressive chemotherapy: a real-world experience
por: Tsuboi, Shinya, et al.
Publicado: (2023)

Promotion of Myelopoiesis in Myelosuppressed Mice by Ganoderma lucidum Polysaccharides
por: Zhu, Xiao-Ling, et al.
Publicado: (2012)

Thiopurine methyltransferase (TPMT) genotyping to predict myelosuppression risk
por: Nguyen, Christine M., et al.
Publicado: (2011)

Multiple drugs: Aseptic Meningitis and myelosuppression: case report
Publicado: (2022)

A randomized, double-blind, multicenter, placebo-controlled phase III trial to evaluate the efficacy and safety of pregabalin in Japanese patients with fibromyalgia
por: Ohta, Hiroyoshi, et al.
Publicado: (2012)

Transfusion practice patterns in patients with anemia receiving myelosuppressive chemotherapy for nonmyeloid cancer: results from a prospective observational study
por: Granfortuna, James, et al.
Publicado: (2018)

Correction to: Higher incidence of pegfilgrastim-induced bone pain in younger patients receiving myelosuppressive chemotherapy: a real-world experience
por: Tsuboi, Shinya, et al.
Publicado: (2023)

Denosumab biosimilar (LY06006) in Chinese postmenopausal osteoporotic women: A randomized, double-blind, placebo-controlled, multicenter phase III study
por: Gu, Jiemei, et al.
Publicado: (2022)

Multicenter, randomized, double‐blinded, placebo‐controlled study of rabacfosadine in dogs with lymphoma
por: Weishaar, Kristen M., et al.
Publicado: (2021)

Complications of MRSA Treatment: Linezolid-induced Myelosuppression Presenting with Pancytopenia
por: Gorchynski, Julie, et al.
Publicado: (2008)

Hematopoietic Effects of Paeoniflorin and Albiflorin on Radiotherapy-Induced Myelosuppression Mice
por: Zhu, Yingli, et al.
Publicado: (2016)

New Insights on Glucosylceramide Synthase in Cancer Drug Resistance and Myelosuppression
por: Gupta, Vineet, et al.
Publicado: (2013)

TGFβ restores hematopoietic homeostasis after myelosuppressive chemotherapy
por: Brenet, Fabienne, et al.
Publicado: (2013)

Cannot write session to /tmp/vufind_sessions/sess_jajd4q4lakfavau5eb6m25frjl